According to WHO data, the global elevated total plasma cholesterol levels among adults aged 25 years and older was as high as 39% in 2008. The prevalence of dyslipidemia among Chinese adults has remained at a high level in recent years. According to the national survey results in 2018, the total prevalence of dyslipidemia in adults ≥18 years old was 35.6%, with the increase of hypercholesterolemia being the most significant. The rate of lipid-lowering treatment and the standard attainment rate in the high (extremely) high risk group of atherosclerotic cardiovascular disease (ASCVD) in China are relatively low, and there is an urgent need for improvement.

The sharp rise in global diabetes incidence in recent years has put increasing pressure on pharmaceuticals to accelerate the research and development of new therapeutics for the disease.In recent years, new hypoglycemic drugs, such as GLP-1RA (glucagon-like peptide-1 receptor agonist) and SGLT2i (sodium-glucose cotransporter 2 inhibitor), have rapidly began to occupy an expanding space in the global market.